Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy

Overview of attention for article published in Core Evidence, April 2019

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (52nd percentile)

Mentioned by

policy: 1 policy source

Citations

dimensions_citation: 21 Dimensions

Readers on

mendeley: 30 Mendeley

Summary Policy documents Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

Idhifa for Acute Myeloid Leukemia – Details

Cited by Canadian Agency for Drugs and Technologies in Health on 01 Jun 2023

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.